Pharmacovigilance & Safety of Biosimilars

Biosimilars are interlinked with FDA activities that have as of now been declared to incorporate upgraded following and follow-up of post market issues, arranged changes in AERS, and pilots of new post advertise medicate observing systems. Current difficulties in pharmacovigilance, adverse medication responses with pharmaceutical items, Biosimilar rules for Pharmacovigilance practice and pharmacoepidemiology are the focuses that should be laid accentuation in this session.

  • Improve Pharmacovigilance through Patient and Provider Education
  • Regulatory updates and key drivers for registration approvals in US, EU and China
  • Regulatory requirement for biosimilar IND filing in the US

Related Conference of Pharmacovigilance & Safety of Biosimilars

November 09-11, 2017

4th European Biopharma Congress

Vienna, Austria
August 20-22, 2018

9th Asian Biologics and Biosimilars Congress

Tokyo, Japan

Pharmacovigilance & Safety of Biosimilars Conference Speakers

Recommended Sessions

Related Journals

Are you interested in